ASX ANNOUNCEMENT **30 July 2026**

Q2 2026 progress in WiSE commercial rollout

Key Highlights

- Limited Market Release (LMR) continued to advance, with 46 WiSE® commercial implants completed during Q2 2026, bringing total implants across the pilot phase and Limited Market Release to 117
- EBR signed 17 new purchasing contracts and trained 26 new physicians during the quarter, bringing cumulative purchasing contracts signed to 52 and trained physicians to 90
- Commercial execution is increasingly focused on deeper utilisation within activated accounts, with more than half now having completed three or more WiSE implants
- EBR expects to report revenue in the range of US$2.50M to US$2.60M for Q2 2026, based on preliminary unaudited quarter-end results and subject to quarter-end closing adjustments
- EBR continues to see positive demand for WiSE, with encouraging numbers of patients being identified and scheduled for H2, 2026

Santa Clara, California; 30 July 2026: EBR Systems, Inc., (ASX: "**EBR**", "**EBR Systems**", or the "**Company**"), developer of the world's only wireless cardiac pacing device for heart failure, provides its preliminary commercial activity update for the quarter ended 30 June 2026.

John McCutcheon, EBR Systems' President & Chief Executive Officer, said:

"Q2 was another successful quarter of commercial execution for EBR, with continued progress across WiSE implant activity, purchasing contracts and physician training.

The Limited Market Release continues to advance, with 46 commercial implants completed during the quarter, bringing total commercial implants to 117. This includes 87 implants completed during calendar year 2026 to 30 June, reflecting continued progress as we build commercial experience across our activated account base.

Given the greater-than-anticipated number of sites contracted, sites activated, and physicians trained at this stage of the LMR, we are directing our commercial team to de-emphasise signing additional sites and training new physicians and to focus more on driving deeper utilisation within existing accounts.

This disciplined approach is designed to support sustainable commercial adoption as we continue to scale our field support, training and operational capabilities."

Continued Commercial Progress

The WiSE® System was implanted in 46 commercial patients during Q2 2026, bringing total implants across the pilot phase and Limited Market Release to 117.

An additional 17 purchasing contracts were signed during the quarter, bringing total purchasing contracts signed to 52.

A total of 90 physicians at 30 sites are now trained to implant the WiSE System, with 26 of these trained during Q2 2026.

As the Limited Market Release matures, EBR is moderating the pace of new site activations and increasing its focus on deeper utilisation within existing activated accounts, supporting repeat procedural experience, internal field capability and more consistent case scheduling.

At 30 June 2026, 30 hospitals had been activated, with 17 sites having completed three or more WiSE implants.







EBR's Q2 activity continues to reflect strong physician demand and institutional recognition of the clinical and economic benefit of the WiSE technology by sites.

The Company believes these are the most important early performance indicators to predict durable commercial success.

Funding, reimbursement and purchasing access

During Q2 2026, EBR partially completed a fully underwritten A$150 million capital raise with the final $A35 million underwritten tranche expected to be completed by 24 Aug 2026 to support its pathway to cashflow breakeven and continued U.S. commercial scale-up. The funding strengthens EBR's balance sheet and supports the Company's ongoing investment in sales and marketing expansion, manufacturing scale-up, cost of goods reduction and continued research and development.

The quarter also included important progress across reimbursement and purchasing access. CMS formally initiated the National Coverage Determination process for WiSE, representing a key milestone in EBR's pathway toward broader Medicare coverage and expanded patient access. EBR also secured purchasing agreements with HCA Healthcare, Advocate Health, and CHRISTUS Health, establishing purchasing pathways across major U.S. healthcare networks and supporting broader hospital access as the U.S. commercial rollout continues.

EBR expects to provide further detail in its Q2 2026 Quarterly Activity Report and Form 10-Q.

Active Investor Engagement

During the quarter, EBR maintained investor, media and industry engagement to support market understanding of the Company's commercial scale-up strategy and the clinical role of the WiSE System.

In April, EBR participated in Heart Rhythm 2026 in Chicago, the major global electrophysiology meeting, providing an opportunity to engage with physicians and industry stakeholders around leadless left ventricular endocardial pacing and the WiSE System. Of note, Dr Niraj Varma (Cleveland Clinic) presented on real-world outcomes from the initial US commercial implants. The headline was a halving of the overall complication rate seen in the SOLVE study (from 19.1% down to 10%).

Following the June capital raise, EBR undertook media interviews and investor-facing commentary focused on the Company's strengthened funding position, CMS National Coverage Determination process, purchasing agreements with major U.S. healthcare networks and broader WiSE commercial rollout.

Preliminary Unaudited Financial Information

The Company has not yet completed its financial close process for the quarter ended 30 June 2026. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in EBR's business, including, without limitation, audit adjustments and other developments that may arise between now and the completion of our year-end financial closing procedures and our independent registered public accounting firm's review of our consolidated financial statements for the quarter ended 30 June 2026. Such preliminary revenue results for quarter ended 30 June 2026, are subject to change, and should not be viewed as a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles. Our independent registered public accounting firm has not audited, nor has it performed any review or other procedures with respect to the preliminary results set forth in this release, nor has it expressed any opinion or any other form of assurance on the preliminary revenue results for Q2 2026 set forth herein.

Investor Webinar

As previously announced, EBR's senior management team will host an investor webinar to discuss these results and the recent announcement regarding online speculation around a complication.

The webinar will be held on **Friday 31 July 2026 at 10:00am AEST (Thursday 30 July at 5:00pm PDT).**

Investors can register for the webinar via the following link:

https://attendee.gotowebinar.com/register/2361333619071585888

After registering, you will receive a confirmation email containing information about joining the webinar.

For more information about EBR, please visit https://www.ebrsystemsinc.com/.

ENDS

This announcement has been authorised for release by the EBR Systems General Disclosure Committee, a Committee of the Board of Directors.

For more information, please contact:

Company
Andrew Shute
Chief Corporate Development Officer
P: +44 7730 691421
E: investor.relations@ebrwise.com

Investor Relations
Gabriella Hold
The Capital Network
P: +61 2 7257 7338
E: gaby@thecapitalnetwork.com.au

Julia Maguire
The Capital Network
P: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About EBR Systems

Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially

(WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems' WiSE Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device in most markets and is currently only available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products and achieve broad market adoption including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. These forward-looking statements are based on EBR Systems' current expectations and inherently involve significant risks and uncertainties. EBR Systems' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in its most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC from time to time and available on the SEC's website at www.sec.gov.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's ASX-traded (ASX: EBR) CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.